Laurus plans to file combination ARVs

Developing and filing first-line and second-line combination antiretrovirals (ARVs) to supply institutional tenders for emerging markets, especially in Africa, forms a key element of Indian bulkdrugs producer Laurus Labs’ plans to push further into the finisheddose formulations (FDFs) sector.